Last reviewed · How we verify
NCT04405895: Liver-CG
Effect of Meal Timing in T2D on Hepatocytes SRIT1 and Clock Genes
NA trial testing Breakfast Diet in Type 2 Diabetes in 24 participants. Status unknown.
20 September 2020
Quick facts
| Lead sponsor | Tel Aviv University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 31 May 2020 |
| Primary completion | 20 September 2020 |
| Estimated completion | 20 October 2020 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Breakfast Diet
- Allday Diet
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Obesity — all drugs for Obesity →
Sponsor
Tel Aviv University
Who can join
Adults 30 to 70, any sex, with Type 2 Diabetes or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is undertaken to explore in T2D, the effect of meal timing on serum induced SIRT1 and Clock Genes mRNA expression in cultured hepatocytes. Fasting serum samples were collected from T2D participants, following two different meal timing schedules, either a diet with large breakfast and lunch with small dinner Breakfast Diet (3Mdiet) or an isocaloric diet with 6 small meals evenly distributed along the day Allday Diet (6Mdiet). The researchers will use an ex-vivo/in-vitro approach in which cultured medium will be conditioned with the fasted human serum collected from the two groups of T2D participants at baseline, after 2 weeks and after 12 week of the diet intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04405895
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Tel Aviv University trials
Trials by the same sponsor.
- NCT07430436 — Improving Self-regulation in Individuals With ADHD Through Adapted Karate Training · NA · not yet recruiting
- NCT07426159 — AI-Guided Sarcopenia Risk Assessment and Detection · NA · active not recruiting
- NCT07364981 — Gaze Contingent Attentional Reinforcement in Major Depressive Disorder · NA · not yet recruiting
- NCT07446127 — Adjunctive Diode Laser Therapy in Non-Surgical Periodontal Therapy · NA · recruiting
- NCT06710145 — The Effect of Using the Combat Attention App on the Risk of Post-traumatic Symptoms · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04405895 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tel Aviv University
- Last refreshed: 28 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04405895.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing